Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Phosphorus containing other than solely as part of an...
Reexamination Certificate
2011-08-02
2011-08-02
Bradley, Christina (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Phosphorus containing other than solely as part of an...
C514S084000, C514S085000, C514S089000, C530S387100, C530S402000, C530S403000
Reexamination Certificate
active
07989434
ABSTRACT:
The present invention provides heterocyclic linker compounds useful for linking drug moieties to ligands. The compounds also include drug-ligand conjugates comprising a ligand capable of targeting a selected cell population, and a drug connected to the ligand by a heterocyclic linker moiety. The linker moiety comprises a peptide sequence that is a substrate for an intracellular enzyme, for example a cathepsin, that cleaves the peptide at an amide bond. The peptide further contains a self-immolating moiety which connects the drug and the protein peptide sequence. Upon cleavage of the peptide sequence by an intracellular enzyme the self-immolating moiety cleaves itself from the drug moiety such that the drug moiety is in an underivatized and active form.
REFERENCES:
patent: 5621002 (1997-04-01), Bosslet et al.
patent: 5877158 (1999-03-01), Bosslet et al.
patent: 6051243 (2000-04-01), Bernardon
patent: 6214345 (2001-04-01), Firestone et al.
patent: 6218519 (2001-04-01), Kenten et al.
patent: 6268488 (2001-07-01), Barbas, III et al.
patent: 6677435 (2004-01-01), Rader et al.
patent: 6759509 (2004-07-01), King et al.
patent: 6835807 (2004-12-01), Susaki et al.
patent: 7091186 (2006-08-01), Senter et al.
patent: 7521541 (2009-04-01), Eigenbrot et al.
patent: 7553816 (2009-06-01), Senter et al.
patent: 7575748 (2009-08-01), Erickson et al.
patent: 2003/0096743 (2003-05-01), Senter et al.
patent: 2003/0130189 (2003-07-01), Senter et al.
patent: 2003/0138432 (2003-07-01), Glazier
patent: 2004/0018194 (2004-01-01), Francisco et al.
patent: 2004/0052793 (2004-03-01), Carter et al.
patent: 2004/0121940 (2004-06-01), De Groot et al.
patent: 2004/0235068 (2004-11-01), Levinson
patent: 2005/0169933 (2005-08-01), Steeves et al.
patent: 2005/0238649 (2005-10-01), Doronina et al.
patent: 2005/0276812 (2005-12-01), Ebens et al.
patent: 2006/0074008 (2006-04-01), Senter et al.
patent: 2006/0247295 (2006-11-01), Gangwar et al.
patent: 2007/0092940 (2007-04-01), Eigenbrot et al.
patent: 2007/0134243 (2007-06-01), Gazzard et al.
patent: 2007/0269446 (2007-11-01), de Sauvage et al.
patent: 2008/0085283 (2008-04-01), Levinson
patent: 2008/0114153 (2008-05-01), Steeves et al.
patent: 2008/0145374 (2008-06-01), Steeves et al.
patent: 2008/0166294 (2008-07-01), de Sauvage et al.
patent: 2008/0171040 (2008-07-01), Ebens et al.
patent: 2008/0171856 (2008-07-01), Steeves et al.
patent: 2008/0171865 (2008-07-01), Steeves et al.
patent: 2008/0226659 (2008-09-01), Erickson et al.
patent: 2009/0202536 (2009-08-01), Ebens et al.
patent: WO98013059 (1998-04-01), None
patent: WO02083180 (2002-10-01), None
patent: WO2004032828 (2004-04-01), None
Carl et al., “A Novel Connector Linkage Applicable in Prodrug Design”, J Med Chem., 24: 479-480 (1981).
Chakravarty et al., “Plasmin-Activated Prodrugs for Cancer Chemotherapy. 2. Synthesis and Biological Activity of Peptidyl Derivatives of Doxorubicin”, J Med Chem, 26:638-644 (1983).
De Groot et al., “Elongated Multiple Electronic Cascade and Cyclization Spacer Systems in Activatible Anticancer Prodrugs for Enhanced Drug Release”, J. Org. Chem., 66:8815-8830 (2001).
De Groot et al., “Design, Synthesis, and Biological Evaluation of a Dual Tumor-specific Motive Containing Integrin-targeted Plasmin-cleavable Doxorubicin Prodrug”, Molecular Cancer Therapeutics, 1:901-911 (2002).
De Groot et al., “Synthesis and Biological Evaluation of Novel Prodrugs of Anthracyclines for Selective Activation by the Tumor-Associated Protease Plasmin”, J. Med Chem, 42:5277-5283 (1999).
Devy et al., “Plasmin-activated doxorubicin prodrugs containing a spacer reduce tumor growth and angiogenesis without systemic toxicity”, FASEB J.,18:565-7 (2004).
Doronina et al., “Development of potent monoclonal antibody auristatin conjugates for cancer therapy”, Nature Biotechnology, 21:778-784 (2003).
Dubowchik et al., “Cathepsin B-Labile Dipeptide Linkers for Lysosomal Release of Doxorubicin from Internalizing Immunoconjugates: Model Studies of Enzymatic Drug Release and Antigen-Specific In Vitro Anticancer Activity”, Bioconjugate Chem., 13:855-869 (2002).
Dubowchik et al., “Cathepsin B-Sensitive Dipeptide Prodrugs. 2. Models of Anticancer Drugs Paclitaxel (Taxol), Mitomycin C and Doxorubicin”, Bioorg Med Chem Lett., 8:3347-3352 (1998).
Dubowchik et al., “Doxorubicin Immunoconjugates Containing Bivalent, Lysosomally-Cleavable Dipeptide Linkages”, Bioorg Med Chem Lett, 12:1529-1532 (2002).
Dubowchik et al., “Efficient Mitomycin C Coupling with Stable p-Nitrophenyl-Benzyl Carbonates using N-Hydroxybenzotriazole as a Catalytic Additive”, Tetrahedron Letters, 38:5261-5264 (1997).
Dubowchik et al., “Monomethoxytrityl (MMT) as a Versatile Amino Protecting Group for Complex Prodrugs of Anticancer Compounds Sensitive to Strong Acids, Bases and Nucleophiles”, Tetrahedron Letters, 38:5257-5260 (1997).
Dubowchik, “Cathepsin B-Sensitive Dipeptide Prodrugs. 1. A Model Study of Structural Requirements for Efficient Release of Doxorubicin”, Bioorg Med Chem Lett., 8:3341-3346 (1998).
Francisco et al., “cAC10-vcMMAE, an anti-CD30 Monomethyl Auristatin E Conjugate with Potent and Selective Antitumor Activity”, Blood, 102:1458-1465 (2003).
Freshney, Culture of Animal Cells, A Manual of Basic Technique, Alan R. Liss, Inc., 1983, New York, p. 4.
Gura, “Systems for Identifying New Drugs are Often Faulty”, Science 278:1041-2 (1997).
Hashimoto et al., “Significance of Cathepsin B Accumulation in Synovial Fluid of Rheumatoid Arthritis”, Biochem Biophys Res Commun., 283:334-339 (2001).
Hay et al., “A 2-Nitromidazole Carbamate Prodrug of 5-Amino-1-(Chloromethyl)-3-[(5,6,7-Trimethoxyindol-2-YL]-1,2-Dihydro-3H-Benz [E] Indole (Amino-Seco-CBI-TMI) for Use with ADEPT and GDEPT”, Bioorg Med Chem Lett., 9:2237-2242 (1999).
King et al., “Monoclonal Antibody Conjugates of Doxorubicin Prepared with Branched Peptide Linkers: Inhibition of Aggregation by Methoxytriethyleneglycol Chains”, J Med Chem., 45:4336-4343 (2002).
Klussman et al., “Secondary mAb-vcMMAE Conjugates Are Highly Sensitive Reporters of Antibody Internalization via the Lysosome Pathway”, Bioconjugate Chemistry, 15:765-773 (2004).
Shabat et al., “Chemical Adaptor Systems”, Chemistry 10: 2626-2634 (2004).
Sinha et al., “Plasma Membrane Association of Cathepsin B in Human Prostate Cancer: Biochemical and Immunogold Electron Microscopic Analysis”, Prostate, 49:172-184 (2001).
Walker et al., “Monoclonal antibody Mediated Intracellular Targeting of Tallysomycin S10b”. Bioorganic & Medicinal Chemistry Letters, 14:4323-4327 (2004).
Zips et al., New Anticancer Agents: In Vitro and In Vivo Evaluation, In Vivo 19:1-8 (2005).
Bradley Christina
Seattle Genetics Inc.
LandOfFree
Heterocyclic self-immolative linkers and conjugates does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Heterocyclic self-immolative linkers and conjugates, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heterocyclic self-immolative linkers and conjugates will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2657793